miss revenu growth expect reduc full year revenu ep
guidanc sign improv busi pharma china mass
spec ta setup share could improv enter howev top
bottom line growth outlook better peer share trade line
peer risk/reward appear balanc current level
constant currenc revenu growth y/i miss consensu expect
overal revenu forecast
consensu rel forecast water divis organ growth wors
expect y/i organ vs y/i forecast ta come better
expect y/i organ vs forecast y/i declin tough
comparison worth call solid pharma growth y/i cc improv
china y/i water divis instrument y/i growth off-set weaker
industri y/i cc europ y/i cc result page detail
gross margin y/i forecast well consensu
oper margin flat y/i came expect driven
much better expect opex ep y/i came
forecast consensu exclud compani share repurchas
program ep would declin lsd y/i
constant currenc revenu growth expect approxim y/i
previou expect y/i reduct larg attribut
cautiou expect europ industri full year ep expect
approxim midpoint guidanc also
expect constant currenc growth guid y/i ep guid
vs consensu
acknowledg anoth rel poor quarterli result guidanc reduct
larg expect link appear sign stabil busi
includ pharma growth y/i q/q improv china y/
growth stabil instrument revenu includ mass spec growth ta
post better fear result tough comparison
beyond growth trajectori continu appear peer averag
level especi bottom line tailwind signific buy-back
diminish exit setup could improv given new product launch
extrem favor comparison howev share appear alreadi give credit
improv fundament stock current trade
price-to-earnings ev/ebitda line peer risk/reward appear
balanc price target repres price-to-earnings ev/ebitda multipl line
peer group median
pleas see page report import disclosur
past year organ revenu growth deceler peer
group averag manag execut also disappoint particularli rel
peer result past sever quarter suggest return
least sustain peer group level revenu growth immin said
buy back market cap end help provid floor
stock price target base mix price-to-earnings discount dcf analysi
slight ev/ebitda discount think adequ justifi reflect
revenu growth improv
favor comparison
downsid ep estim limit
revenu growth acceler
driven favor comparison
new product
great cash flow return profil
macroeconom competit
current expect
limit room margin improv
continu slower expect growth
caus investor revisit inher
growth rate compani appropri
corpor analyt instrument manufactur
divis design manufactur sell servic high-perform liquid
chromatographi hplc ultra perform liquid chromatographi uplc togeth
hplc refer lc mass spectrometri ms instrument system support
product includ chromatographi column consum product post-
warranti servic plan ta divis ta compani primarili design
manufactur sell servic thermal analysi rheometri calorimetri instrument
compani also develop supplier software-bas product interfac
compani instrument well manufactur instrument
compani report thomson eikon cowen compani
cowen vs consensu mm except cc fx y/i re-affirmed cc growth fx y/ygross revenu metric mm except statement mm except currenc per count came expect sale sg came expect sale oper margin came better expect driven better expect opex despit weaker sale result tax rate slightli higher water divis organ growth y/i came expect rel model instrument revenu larg line weak driven recur revenu growth end market pharma post solid growth y/i academic/gov flat industrial/appli declin y/i geographi america y/i solid asia improv y/i includ growth china europ continu weak ta organ revenu declin y/i better expect encouragingli instrument revenu appear flat y/i vs incred difficult comparison off-set servic weak look detail call regard sustain revenu growth y/i came consensu expect full year guidanc also reduc impli reduct growth expect anoth rel weak quarter encourag sign includ pharma growth improv china result q/q stabil instrument revenu least appear provid confid trend deterior gross margin expect ep came forecast consensu ep growth y/i though exclud robust share repurchas program ep would declin lsd y/i cowen
compani report cowen compani
mm except per share cagrcommentstot cc cc previous fx y/i re-affirmed growth cc growth fx y/yconst currenc growth growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth cowen
compani report thomson eikon cowen compani
mm except cagrcommentsnet cc cc previous fx y/i cc growth fx y/yorgan currenc re-affirmed leverag sg grown revenu oper oper expens growth sale growth get leverag non-oper interest re-affirmed tax earn per dilut share count cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk upsid includ limit recoveri macroeconom condit
increas client budget demand lc/m instrument consum better
expect product innov associ revenu contribut share gain risk
downsid includ limit macroeconom deterior current
level inabl execut integr eros market share price due
competit inabl deliv incremental/decrement margin target value-
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen cross-asset research due natur fix incom market issuer debt secur issuer discuss cowen cross-asset research report
assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon analysi reflect
analyst opinion date report expect continu analysi addit report relat issuer debt secur issuer
time time cowen cross-asset research analyst provid invest recommend secur subject report recommend intend
time date public within paramet specifi individu report cowen cross-asset research invest recommend made
strictli case-by-cas basi recommend provid part overarch rate system set consist appli benchmark view express
cross-asset research report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc juli et dissemin juli et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
